StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.76+0.06 (+0.78%)

Close on Nov 13, 2026Market cap $416.17MP/E –Yield –

Avalo Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Avalo Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$95.49M. For fiscal 2025 it was -$72.58M. The highest annual figure on record is $14.32M in fiscal 2017.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$72.58M–
FY2024Dec 31, 2024-$68.34M–
FY2023Dec 31, 2023-$27.19M–
FY2022Dec 31, 2022-$37.27M–
FY2021Dec 31, 2021-$80.48M–
FY2020Dec 31, 2020-$71.00M–
FY2019Dec 31, 2019-$12.25M–
FY2018Dec 31, 2018-$30.82M-315.3%
FY2017Dec 31, 2017$14.32M–
FY2016Dec 31, 2016-$16.05M–
FY2015Dec 31, 2015-$10.99M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$23.38M–
Q2 FY2026Jun 30, 2026-$31.50M–
Q1 FY2026Mar 31, 2026-$20.88M–
Q4 FY2025Dec 31, 2025-$19.73M–
Q3 FY2025Sep 30, 2025-$19.14M–
Q2 FY2025Jun 30, 2025-$19.18M–
Q1 FY2025Mar 31, 2025-$14.53M–
Q4 FY2024Dec 31, 2024-$13.24M–
Q3 FY2024Sep 30, 2024-$12.83M–
Q2 FY2024Jun 30, 2024-$9.54M–
Q1 FY2024Mar 31, 2024-$32.73M–
Q4 FY2023Dec 31, 2023-$7.62M–
Q3 FY2023Sep 30, 2023-$3.71M-189.8%
Q2 FY2023Jun 30, 2023-$7.11M–
Q1 FY2023Mar 31, 2023-$8.76M–
Q4 FY2022Dec 31, 2022-$8.82M–
Q3 FY2022Sep 30, 2022$4.13M–
Q2 FY2022Jun 30, 2022-$11.80M–
Q1 FY2022Mar 31, 2022-$20.79M–
Q4 FY2021Dec 31, 2021-$17.67M–
Q3 FY2021Sep 30, 2021-$16.01M–
Q2 FY2021Jun 30, 2021-$16.67M–
Q1 FY2021Mar 31, 2021-$30.13M–
Q4 FY2020Dec 31, 2020-$15.80M–
Q3 FY2020Sep 30, 2020-$12.85M–
Q2 FY2020Jun 30, 2020-$11.39M–
Q1 FY2020Mar 31, 2020-$30.96M–
Q4 FY2019Dec 31, 2019-$5.11M–
Q3 FY2019Sep 30, 2019-$1.80M–
Q2 FY2019Jun 30, 2019-$1.44M–
Q1 FY2019Mar 31, 2019-$3.91M–
Q4 FY2018Dec 31, 2018-$336.47K–
Q3 FY2018Sep 30, 2018-$23.24M-206.0%
Q2 FY2018Jun 30, 2018-$4.51M–
Q1 FY2018Mar 31, 2018-$2.73M–
Q4 FY2017Dec 31, 2017-$3.95M–
Q3 FY2017Sep 30, 2017$21.93M–
Q2 FY2017Jun 30, 2017-$1.77M–
Q1 FY2017Mar 31, 2017-$1.89M–

More Avalo Therapeutics figures

See a number that looks wrong?